Journals listed in Web of Science and JCR receive many submissions and desk reject a large share. A section-by-section audit by a PhD reviewer in your area shows what to fix first.
Manuscript Auditing →01Impact factor
Impact factor of Acta Poloniae Pharmaceutica (2026)
The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Acta Poloniae Pharmaceutica published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, applied to the open citation data of OpenAlex. The journal is listed in JCR 2024, so it also has an official Journal Impact Factor published by Clarivate, which can differ because it counts citations from Web of Science journals only.
Rank in its subject categories
- Q4Pharmacology & Pharmacyrank 346 of 371 journals
Quartiles here rank journals of the same Web of Science category by 2-year citedness; they are not the official JCR quartiles.
Citations and papers per year
Open access (listed in DOAJ).
02Indexing
Indexing of Acta Poloniae Pharmaceutica
- ISSN
- 0001-6837
- eISSN
- 2353-5288
- Publisher
- Polskie Towarzystwo Farmaceutyczne
- Country
- Poland
- Language
- English
- Web of Science categories
- Pharmacology & Pharmacy
From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor and quartile on this page are calculated from OpenAlex open data (see how the impact factor works).
03What it publishes
What Acta Poloniae Pharmaceutica publishes: real papers
04Papers by our mentors
Papers by ScholarsColab mentors in Acta Poloniae Pharmaceutica
- Synthesis, characterization, antimicrobial and phytotoxic screening of 1-aroyl-3, 5-diarylpyrazoline derivatives20157 citations
Dr Muhammad Atif
05Reviewer comments
Reviewer comments and rejection reasons for Acta Poloniae Pharmaceutica
No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.
Share reviewer comments for this journal →Planning to submit here? A Manuscript Audit by a PhD reviewer in your area checks your paper for the issues reviewers raise most often.
Get a Manuscript Audit →Preparing to submit here? Make sure reviewers don't stop at the issues they raise most often. A PhD reviewer in your area can audit your manuscript section by section, and we can convert it into the journal's LaTeX template.
06Similar journals
Journals similar to Acta Poloniae Pharmaceutica
Journals where our mentors published the closest work to the papers above:
- Pakistan Journal Of Pharmaceutical SciencesJCR 20245 mentor papers
- European Chemical BulletinScopus14 mentor papers
- Asian Journal of ChemistryScopus13 mentor papers
- Journal of Molecular StructureSCIEScopusJCR 202447 mentor papers
- Egyptian Journal of ChemistryESCIScopusJCR 202417 mentor papers
- Global NexusNot found in our indexing lists2 mentor papers
07Journal Finder
Find the right journal for your paper
Is Acta Poloniae Pharmaceutica right for your paper? Compare journals
Paste your title, keywords or abstract. We match it against 28,582 journal papers published by PhD researchers on ScholarsColab and show where the closest work appeared, with each journal’s indexing (SCIE, SSCI, AHCI, ESCI, Scopus, JCR 2024).
How it works: no AI or language model is used. Your words are matched against the titles of real published papers by our mentors; journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; “not found in our indexing lists” does not prove a journal is unindexed. Always check a journal’s scope and current indexing before submitting.
08Questions
Frequently asked questions
What is the impact factor of Acta Poloniae Pharmaceutica?
Based on OpenAlex citation data (October 2026), the 2-year impact factor of Acta Poloniae Pharmaceutica is 0.43: papers it published in the two previous years were cited 0.43 times on average in a year. The journal is listed in JCR 2024, so Clarivate also publishes an official Journal Impact Factor, which can differ.
What is the h-index of Acta Poloniae Pharmaceutica?
The h-index of Acta Poloniae Pharmaceutica is 14 (OpenAlex, October 2026): 14 of its papers have each been cited at least 14 times. Its i10-index is 25.
Is Acta Poloniae Pharmaceutica a Q4 journal?
By 2-year citedness, Acta Poloniae Pharmaceutica ranks 346 of 371 journals in Pharmacology & Pharmacy, which places it in Q4 of that Web of Science category. This ranking is calculated by ScholarsColab from OpenAlex data; the official JCR quartile can differ.
Is Acta Poloniae Pharmaceutica indexed in Scopus?
Acta Poloniae Pharmaceutica was not found in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Acta Poloniae Pharmaceutica an SCIE journal?
Yes. Acta Poloniae Pharmaceutica is listed in the Science Citation Index Expanded (SCIE), according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Acta Poloniae Pharmaceutica in Journal Citation Reports (JCR)?
Yes. Acta Poloniae Pharmaceutica is listed in JCR 2024, so it has a Journal Impact Factor. For the current impact factor and quartile, check Journal Citation Reports.
Have ScholarsColab mentors published in Acta Poloniae Pharmaceutica?
Yes. 1 paper by 1 mentor was published in Acta Poloniae Pharmaceutica in 2015, with 7 citations in total.
Want a PhD expert to choose the journal with you?
Our Journal Selection & Submission service shortlists up to 5 journals that match your manuscript, indexing requirement and target quartile, and handles the submission. If your paper was rejected before, a Manuscript Audit shows what to fix first.